Health Catalyst (NASDAQ:HCAT) Price Target Lowered to $2.00 at Stifel Nicolaus

Health Catalyst (NASDAQ:HCAT) had its price objective decreased by Stifel Nicolaus from $3.75 to $2.00 in a research report released on Friday,Benzinga reports. Stifel Nicolaus currently has a hold rating on the stock.

Several other equities analysts have also recently issued reports on HCAT. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Health Catalyst in a research report on Monday, December 29th. Raymond James Financial set a $3.00 price target on Health Catalyst in a research note on Friday. Citigroup lowered their price target on Health Catalyst from $3.25 to $2.75 and set a “neutral” rating on the stock in a report on Friday, January 9th. Canaccord Genuity Group dropped their price objective on Health Catalyst from $5.00 to $2.00 and set a “buy” rating on the stock in a research report on Friday. Finally, Cantor Fitzgerald reduced their price objective on Health Catalyst from $4.00 to $3.00 and set a “neutral” rating for the company in a report on Friday. Five equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $3.16.

Health Catalyst Stock Down 26.3%

Shares of Health Catalyst stock opened at $1.32 on Friday. The company has a 50-day simple moving average of $2.05 and a two-hundred day simple moving average of $2.57. The stock has a market capitalization of $93.36 million, a PE ratio of -0.52 and a beta of 1.76. Health Catalyst has a 52-week low of $1.20 and a 52-week high of $5.06. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.88 and a current ratio of 1.88.

Health Catalyst (NASDAQ:HCAT) last posted its quarterly earnings results on Thursday, March 12th. The company reported $0.08 EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.02). The firm had revenue of $74.68 million for the quarter, compared to analysts’ expectations of $73.99 million. Health Catalyst had a negative net margin of 57.20% and a negative return on equity of 3.98%. On average, analysts anticipate that Health Catalyst will post -0.33 EPS for the current fiscal year.

Institutional Investors Weigh In On Health Catalyst

A number of hedge funds have recently added to or reduced their stakes in HCAT. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Health Catalyst by 7.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 36,047 shares of the company’s stock valued at $163,000 after buying an additional 2,624 shares during the period. Campbell & CO Investment Adviser LLC grew its holdings in shares of Health Catalyst by 9.7% in the second quarter. Campbell & CO Investment Adviser LLC now owns 43,051 shares of the company’s stock worth $162,000 after acquiring an additional 3,808 shares during the period. The Manufacturers Life Insurance Company increased its position in Health Catalyst by 19.6% during the second quarter. The Manufacturers Life Insurance Company now owns 26,491 shares of the company’s stock valued at $100,000 after acquiring an additional 4,341 shares during the last quarter. BNP Paribas Financial Markets increased its position in Health Catalyst by 71.7% during the third quarter. BNP Paribas Financial Markets now owns 16,355 shares of the company’s stock valued at $47,000 after acquiring an additional 6,832 shares during the last quarter. Finally, Invesco Ltd. lifted its holdings in Health Catalyst by 6.5% in the fourth quarter. Invesco Ltd. now owns 118,591 shares of the company’s stock valued at $283,000 after acquiring an additional 7,186 shares during the period. 85.00% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Health Catalyst

Here are the key news stories impacting Health Catalyst this week:

• Positive Sentiment: Revenue and some profitability metrics showed resilience: Q4 revenue slightly beat consensus ($74.68M vs. $73.99M) and the company reported full‑year revenue of $311.1M with Adjusted EBITDA of $41.4M — signals that core demand remains. Health Catalyst Reports Fourth Quarter and Year End 2025 Results
• Positive Sentiment: Some chart/analyst commentary suggests the stock may be finding technical support (hammer pattern) and that earnings‑estimate revisions could stabilize — a possible near‑term bottom for opportunistic buyers. HCAT May Find a Bottom Soon
• Neutral Sentiment: Management has launched a strategic review and the CEO would not rule out a potential sale — this could unlock value but also creates uncertainty around capital allocation and timing. Seeking Alpha: CEO declines to rule out sale
• Negative Sentiment: The quarter showed an EPS miss and continued negative margins — Q4 EPS missed estimates (reported ~$0.08 vs. consensus around $0.10), which undercut confidence in near‑term profitability. MarketBeat Q4 results summary
• Negative Sentiment: Q1 revenue guidance was lowered to $68.0M–$70.0M vs. consensus ~ $74.1M — the guidance shortfall appears to be the main driver of the selloff since it signals softer near‑term top‑line momentum. Earnings press release / guidance
• Negative Sentiment: Multiple sell‑side firms lowered price targets and moved to neutral/hold/equal‑weight (Citigroup to $1.75, Stephens and Stifel to $2.00), increasing downward pressure and reducing buy‑side conviction. Analyst price-target cuts (Benzinga)
• Negative Sentiment: Market reaction was amplified by heavy volume and headlines emphasizing the mixed print and management uncertainty, leading to sharp intraday selling despite the revenue beat. MSN: stock reaction

About Health Catalyst

Health Catalyst (NASDAQ: HCAT) is a healthcare data and analytics technology company founded in 2008 and headquartered in Salt Lake City, Utah. The company went public in 2019 and has since focused on delivering a unified data platform that helps healthcare organizations aggregate and analyze clinical, financial and operational information.

The core of Health Catalyst’s offering is the Data Operating System (DOS), a modular data management platform that integrates disparate data sources—from electronic health records to claims and patient-generated data—into a single analytics environment.